Chardan analyst Janani Sundararajan downgraded Passage Bio (PASG) to Neutral from Buy with a $7 price target following the company’s decision to pursue strategic alternatives. The firm sees uncertainty around Passage’s next steps.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PASG: